Endometriosis: Epidemiology, Risk Factors, Molecular Mechanisms, Diagnosis, and Management

Abstract

Endometriosis is a chronic estrogen-dependent gynecological disorder characterized by the ectopic growth of endometrial-like tissue outside the uterine cavity, affecting approximately 10% of women of reproductive age worldwide. It is a leading cause of chronic pelvic pain, dysmenorrhea, and infertility, imposing a substantial burden on individual health and healthcare systems. Despite decades of research, the pathogenesis of endometriosis remains incompletely elucidated, and clinical management is often limited by delayed diagnosis and suboptimal treatment efficacy. This review provides a comprehensive and updated overview of endometriosis, covering its updated epidemiology, established and emerging risk factors, and key molecular mechanisms including inflammation, epigenetic regulation, hormonal imbalance, oxidative stress, and abnormal cell invasion and proliferation. We further summarize current diagnostic approaches, including imaging modalities, laparoscopy, and biomarkers, as well as clinical management strategies such as hormonal therapy, surgical intervention, and emerging targeted treatments. Finally, we discuss existing diagnostic and therapeutic challenges, unresolved questions, and future directions toward precision medicine and noninvasive management. This review aims to integrate recent advances and provide an updated framework for understanding and improving the clinical care of endometriosis. This review also highlights actionable translational directions for noninvasive early diagnosis, precision targeted therapy, and postoperative recurrence prevention, providing a key theoretical framework for translating basic research findings into clinical practice.

Keywords

diagnosis / endometriosis / epidemiology / management / molecular mechanisms

References

[1] P. G. Signorile, A. Baldi, R. Viceconte, A. Ronchi, and M. Montella, “Pathogenesis of Endometriosis: Focus on Adenogenesis-related Factors,” In Vivo 37, no. 5 (2023): 1922–1930.

[2] C. Harder, R. V. Velho, I. Brandes, J. Sehouli, and S. Mechsner, “Assessing the True Prevalence of Endometriosis: a Narrative Review of Literature Data,” Int J Gynecol Obstet 167, no. 3 (2024): 883–900.

[3] N. A. Szylit, L. C. P. Raiza, A. A. S. Leal, and S. Podgaec, “Epidemiology With Real-world Data: Deep Endometriosis in Women of Reproductive Age,” Einstein-Sao Paulo (2025): 23. eAO1259.

[4] E. Pasalic, M. M. Tambuwala, and A. Hromic-Jahjefendic, “Endometriosis: Classification, Pathophysiology, and Treatment Options,” Pathology, Research and Practice 251 (2023): 154847.

[5] T. Maulenkul, A. Kuandyk, D. Makhadiyeva, et al., “Understanding the Impact of Endometriosis on Women's Life: an Integrative Review of Systematic Reviews,” Bmc Womens Health 24, no. 1 (2024): 524.

[6] P. S. Thiel, O. Bougie, J. Pudwell, J. Shellenberger, M. P. Velez, and A. Murji, “Endometriosis and Mental Health: a Population-based Cohort Study,” American Journal of Obstetrics and Gynecology 230, no. 6 (2024): 649.e1–649.e19.

[7] Y. H. Shih, S. J. Wang, C. T. Fan, et al., “Long-term Risk of Psychiatric Disorders in Women with Endometriosis: a Retrospective Cohort Study,” Compr Psychiat 144 (2026): 152649.

[8] Z. Y. Liu, P. G. Chen, L. L. Luo, Q. R. Liu, H. Shi, and X. Yang, “Causal Effects of Gut Microbiome on Endometriosis: a Two-sample Mendelian Randomization Study,” Bmc Womens Health 23, no. 1 (2023): 637.

[9] P. Venkatesan, “Bacterial Infection Linked to Endometriosis,” The Lancet Microbe 10, no. 10 (2023): e768–e768.

[10] Y. Q. Wei, Z. R. Zhang, Y. Y. Zhang, et al., “Nontargeted Metabolomics Analysis of Follicular Fluid in Patients with Endometriosis Provides a New Direction for the Study of Oocyte Quality,” Medcomm 4, no. 3 (2023): e302.

[11] D. Y. Shen, J. Li, P. W. Hu, C. Qi, and H. Yang, “Global, Regional, and National Prevalence and Disability-adjusted Life-years for Endometriosis in 204 Countries and territories, 1990–2019: Findings from a Global Burden of Disease Study,” Eur J Obst Gyn R B-X 25 (2025): 100363.

[12] S. F. Xu, Y. Zhang, P. Ye, et al., “Global, Regional, and National Burden of Endometriosis among Women of Childbearing Age from 1990 to 2021: a Cross-sectional Analysis from the 2021 Global Burden of Disease Study,” Int J Surg 111, no. 9 (2025): 5927–5940.

[13] U. L. R. Maggiore, V. Chiappa, M. Ceccaroni, et al., “Epidemiology of Infertility in Women with Endometriosis,” Best Pract Res Cl Ob 92 (2024): 102454.

[14] H. L. Yan, X. Y. Li, Y. Dai, et al., “Global, Regional, and National Burdens of Endometriosis from 1990 to 2021: a Trend Analysis,” Front Med-Lausanne 12 (2025): 1562196.

[15] R. J. Li, L. Zhang, and Y. Liu, “Global and Regional Trends in the Burden of Surgically Confirmed Endometriosis from 1990 to 2021,” Reprod Biol Endocrin 23, no. 1 (2025): 88.

[16] N. Rzewuska, M. Kunicki, S. Mechsner, and P. Kordowitzki, “Rare Clinical Presentation of Postmenopausal Endometriosis: a New Perspective,” Aging Dis 15, no. 6 (2024): 2361–2368.

[17] B. Swift, B. Taneri, C. M. Becker, et al., “Prevalence, Diagnostic Delay and Economic Burden of Endometriosis and Its Impact on Quality of Life: Results from an Eastern Mediterranean Population,” European Journal of Public Health 34, no. 2 (2024): 244–252.

[18] G. Christman, M. Cole, K. Edsall, S. DePaauw-Holt, C. Schuler, and C. Lickert, “The Clinical and Economic Burden of Woman With Endometriosis (Em),” Value in Health: The Journal of the International Society for Pharmacoeconomics and Outcomes Research 27, no. 6 (2024): S377–S378.

[19] C. M. King, K. Shelley, and E. Hsiao, “Economic Burden of Endometriosis: a Systematic Literature Review,” Value in Health: The Journal of the International Society for Pharmacoeconomics and Outcomes Research 23 (2020): S156–S156.

[20] A. M. Soliman, E. Surrey, M. Bonafede, J. K. Nelson, and J. Castelli-Haley, “Real-World Evaluation of Direct and Indirect Economic Burden among Endometriosis Patients in the United States,” Advances in Therapy 35, no. 3 (2018): 408–423.

[21] D. Szczesna, K. Wieczorek, and J. Jurewicz, “An Exposure to Endocrine Active Persistent Pollutants and Endometriosis—A Review of Current Epidemiological Studies,” Environ Sci Pollut R 30, no. 6 (2023): 13974–13993.

[22] D. Sirohi, R. Al Ramadhani, and L. D. Knibbs, “Environmental Exposures to Endocrine Disrupting Chemicals (EDCs) and Their Role in Endometriosis: a Systematic Literature Review,” Reviews on Environmental Health 36, no. 1 (2021): 101–115.

[23] V. M. Vazgiourakis, M. I. Zervou, L. Papageorgiou, et al., “Association of Endometriosis with Cardiovascular Disease: Genetic Aspects (Review),” International Journal of Molecular Medicine 51, no. 3 (2023): 29.

[24] C. Rees, E. Gabriels, A. Siebers, M. Westerhuis, B. Schoot, and H. Van Vliet, “Endometriosis and Adenomyosis in Relation to Obstetric Outcomes: a Dutch Population-based Cohort Study,” Human Reproduction (2025): 40.

[25] P. S. Munksgaard and J. Blaakaer, “The Association between Endometriosis and Ovarian Cancer: a Review of Histological, Genetic and Molecular Alterations,” Gynecologic Oncology 124, no. 1 (2012): 164–169.

[26] A. I. G. Bausic, F. Scurtu, A. Manu, D. R. Matasariu, and E. Bratila, “Gut Microbiota Dysbiosis in Endometriosis: a Potential Link to Inflammation and Disease Progression,” International Journal of Molecular Sciences 26, no. 11 (2025): 5144.

[27] F. Facciotti, G. Di Stefano, P. Maragno, et al., “Microbiome Dysbiosis and Endometriosis: a Systematic Scoping Review of Current Literature and Knowledge Gaps,” Hum Reprod Open 2025, no. 4 (2025): hoaf061.

[28] C. S. Gallagher, N. Mäkinen, H. R. Harris, et al., “Genome-wide Association and Epidemiological Analyses Reveal Common Genetic Origins between Uterine Leiomyomata and Endometriosis,” Nature Communications 10, no. 1 (2019): 4857.

[29] R. Saha, H. J. Pettersson, P. Svedberg, et al., “Heritability of Endometriosis,” Fertility and Sterility 104, no. 4 (2015): 947–952.

[30] R. Saha, L. Marions, and P. Tornvall, “Validity of Self-reported Endometriosis and Endometriosis-related Questions in a Swedish Female Twin Cohort,” Fertility and Sterility 107, no. 1 (2017): 174-+.

[31] J. N. Fung, P. A. W. Rogers, and G. W. Montgomery, “Identifying the Biological Basis of GWAS Hits for Endometriosis,” Biology of Reproduction 92, no. 4 (2015): 87.

[32] D. Koller, G. A. Pathak, F. R. Wendt, et al., “Epidemiologic and Genetic Associations of Endometriosis with Depression, Anxiety, and Eating Disorders,” JAMA Network Open 6, no. 1 (2023): e2251214.

[33] N. Rahmioglu, D. R. Nyholt, A. P. Morris, S. A. Missmer, G. W. Montgomery, and K. T. Zondervan, “Genetic Variants Underlying Risk of Endometriosis: Insights from Meta-analysis of Eight Genome-wide Association and Replication Datasets,” Human Reproduction Update 20, no. 5 (2014): 702–716.

[34] P. T. K. Saunders, “Insights from Genomic Studies on the Role of Sex Steroids in the Aetiology of Endometriosis,” Reprod Fertil 3, no. 2 (2022): R51–R65.

[35] E. Giacomini, S. Minetto, L. Li Piani, L. Pagliardini, E. Somigliana, and P. Viganò, “Genetics and Inflammation in Endometriosis: Improving Knowledge for Development of New Pharmacological Strategies,” International Journal of Molecular Sciences 22, no. 16 (2021): 9033.

[36] M. Arleevskaya, E. Takha, S. Petrov, et al., “Interplay of Environmental, Individual and Genetic Factors in Rheumatoid Arthritis Provocation,” International Journal of Molecular Sciences 23, no. 15 (2022): 8140.

[37] J. Pan, P. F. Liu, X. Yu, Z. M. Zhang, and J. X. Liu, “The Adverse Role of Endocrine Disrupting Chemicals in the Reproductive System,” Front Endocrinol 14 (2024): 1324993.

[38] M. Puri, K. Gandhi, and M. S. Kumar, “A Global Overview of Endocrine Disrupting Chemicals in the Environment: Occurrence, Effects, and Treatment Methods,” Int J Environ Sci Te 20, no. 11 (2023): 12875–12902.

[39] D. Szukiewicz, “Insight into the Potential Mechanisms of Endocrine Disruption by Dietary Phytoestrogens in the Context of the Etiopathogenesis of Endometriosis,” International Journal of Molecular Sciences 24, no. 15 (2023): 12195.

[40] Z. F. Zhang, H. Alomirah, H. S. Cho, et al., “Urinary Bisphenol A Concentrations and Their Implications for Human Exposure in Several Asian Countries,” Environmental Science & Technology 45, no. 16 (2011): 7044–7050.

[41] F. M. Peinado, I. Lendínez, R. Sotelo, et al., “Association of Urinary Levels of Bisphenols A, F, and S with Endometriosis Risk: Preliminary Results of the EndEA Study,” Int J Env Res Pub He 17, no. 4 (2020): 1194.

[42] A. Simonelli, R. Guadagni, P. De Franciscis, et al., “Environmental and Occupational Exposure to Bisphenol A and Endometriosis: Urinary and Peritoneal Fluid Concentration Levels,” Int Arch Occ Env Hea 90, no. 1 (2017): 49–61.

[43] B. Ribeiro, M. Mariana, M. Lorigo, D. Oliani, A. C. Ramalhinho, and E. Cairrao, “Association between the Exposure to Phthalates and the Risk of Endometriosis: an Updated Review,” Biomedicines 12, no. 8 (2024): 1932.

[44] H. Yi, H. M. Wu, W. B. Zhu, et al., “Phthalate Exposure and Risk of Ovarian Dysfunction in Endometriosis: Human and Animal Data,” Frontiers in Cell and Developmental Biology 11 (2023): 1154923.

[45] Y. L. Chen, Y. T. Jiang, Z. Y. Li, et al., “The Effect of Phytoestrogens and PAHs on Endometriosis and the Involvement of Gut Microbiota, Inflammation, and Molecular Targets,” Sci Rep-Uk 15, no. 1 (2025): 36027.

[46] A. Vallée, P. F. Ceccaldi, M. Carbonnel, A. Feki, and J. M. Ayoubi, “Pollution and Endometriosis: a Deep Dive into the Environmental Impacts on Women's Health,” Bjog-Int J Obstet Gy 131, no. 4 (2024): 401–414.

[47] A. Vallée, A. Feki, L. Josseran, and J. M. Ayoubi, “Smoking and Endometriosis: a Narrative Review,” Tob Induc Dis (2025): 23.

[48] F. Chiaffarino, S. Cipriani, P. Viganò, E. Somigliana, and F. Parazzini, “A Systematic Review and Meta-analysis on Alcohol Consumption and Risk of Endometriosis: an Update From 2012,” Sci Rep-Uk 12, no. 1 (2022): 19122.

[49] G. S. Jung, J. H. Lee, M. J. Lee, et al., “Effects of Chronic Particulate Matter Exposure on Endometriosis-associated Signaling Pathways and Disease Progression,” Molecular Human Reproduction 31, no. 2 (2025): gaaf013.

[50] X. Zhang, Q. M. Zheng, and L. H. Chen, “Dietary Factors and Risk for Endometriosis: a Mendelian Randomization Analysis,” Nutrition and Metabolism 22, no. 1 (2025): 72.

[51] A. Arab, E. Karimi, K. Vingrys, M. R. Kelishadi, S. Mehrabani, and G. Askari, “Food Groups and Nutrients Consumption and Risk of Endometriosis: a Systematic Review and Meta-analysis of Observational Studies,” Nutr J 21, no. 1 (2022): 58.

[52] Y. Huang, W. J. Zhou, L. Zhu, and D. D. Ni, “Omega-3 Polyunsaturated Fatty Acid Intake and Pain, Inflammatory Cytokines, and Quality of Life in Endometriosis,” Frontiers in Nutrition 13, no. 4 (2026): 1768244.

[53] B. L. Xie, M. Liao, Y. Q. Huang, et al., “Association between Vitamin D and Endometriosis among American Women: National Health and Nutrition Examination Survey,” PLoS ONE 19, no. 1 (2024): e0296190.

[54] O. N. Shrateh, H. A. Siam, Y. S. Ashhab, R. R. Sweity, and M. Naasan, “The Impact of Vitamin D Treatment on Pregnancy Rate among Endometriosis Patients: a Systematic Review and Meta-analysis,” Ann Med Surg 86, no. 7 (2024): 4098–4111.

[55] S. Rahman, Y. Park, H. Hosseinirad, J. H. Shin, and J. W. Jeong, “The Interplay between Endometriosis and Obesity,” Trends Endocrin Met 36, no. 12 (2025): 1140–1153.

[56] I. J. Rowlands, R. Hockey, J. A. Abbott, G. W. Montgomery, and G. D. Mishra, “Body Mass Index and the Diagnosis of Endometriosis: Findings from a National Data Linkage Cohort Study,” Obes Res Clin Pract 16, no. 3 (2022): 235–241.

[57] E. Piriyev, C. Mennicken, S. Schiermeier, and T. Roemer, “Does BMI Have an Impact on Endometriosis Symptoms and Endometriosis Types According to the #ENZIAN Classification?,” Journal of Clinical Medicine 14, no. 12 (2025): 4040.

[58] M. Xie, X. M. Qing, H. L. Huang, et al., “The Effectiveness and Safety of Physical Activity and Exercise on Women with Endometriosis: a Systematic Review and Meta-analysis,” PLoS ONE 20, no. 2 (2025): e0317820.

[59] C. Tourny, A. Zouita, S. El Kababi, et al., “Endometriosis and Physical Activity: a Narrative Review,” Int J Gynecol Obstet 163, no. 3 (2023): 747–756.

[60] I. E. Oala, M. I. Mitranovici, D. M. Chiorean, et al., “Endometriosis and the Role of Pro-Inflammatory and Anti-Inflammatory Cytokines in Pathophysiology: a Narrative Review of the Literature,” Diagnostics 14, no. 3 (2024): 312.

[61] X. Y. Xu, J. Li, H. Lin, Z. Lin, and G. C. Ji, “The Role of TGF-β Superfamily in Endometriosis: a Systematic Review,” Frontiers in immunology 16 (2025): 1638604.

[62] B. J. Yang, F. Li, G. M. Cao, et al., “Mechanistic Insights into Inflammatory Cytokines in Adenomyosis-induced Infertility (Review),” International Journal of Molecular Medicine 57, no. 5 (2026): 107.

[63] M. Abramiuk, E. Grywalska, P. Malkowska, O. Sierawska, R. Hrynkiewicz, and P. Niedzwiedzka-Rystwej, “The Role of the Immune System in the Development of Endometriosis,” Cells-Basel 11, no. 13 (2022): 2028.

[64] A. Luddi, C. Marrocco, L. Governini, et al., “Expression of Matrix Metalloproteinases and Their Inhibitors in Endometrium: High Levels in Endometriotic Lesions,” International Journal of Molecular Sciences 21, no. 8 (2020): 2840.

[65] Y. Deng and Q. Liu, “The Role of the CXC Chemokine family in Endometriosis Research and Its Therapeutic Potential,” Journal of Molecular Histology 56, no. 4 (2025): 211.

[66] Y. Peng, Y. H. Li, L. M. Wang, S. L. Lin, and H. Xu, “Causality of Immune Cells and Endometriosis: a Bidirectional Mendelian Randomization Study,” Bmc Womens Health 24, no. 1 (2024): 574.

[67] M. Z. Moghaddam, H. Ansariniya, S. M. Seifati, F. Zare, and F. Fesahat, “Immunopathogenesis of Endometriosis: an Overview of the Role of Innate and Adaptive Immune Cells and Their Mediators,” American Journal of Reproductive Immunology 87, no. 5 (2022): e13537.

[68] X. R. Wang, N. Wu, and Q. Xue, “Macrophages in Endometriosis: Key Roles and Emerging Therapeutic Opportunities-a Narrative Review,” Reprod Biol Endocrin 23, no. 1 (2025): 134.

[69] L. Y. Chang, J. Shan, X. X. Hou, D. J. Li, and X. Q. Wang, “Synergy between Th1 and Th2 Responses during Endometriosis: a Review of Current Understanding,” Journal of Reproductive Immunology 158 (2023): 103975.

[70] J. Knez, B. Kovacic, and A. Goropevsek, “The Role of Regulatory T-cells in the Development of Endometriosis,” Human Reproduction 39, no. 7 (2024): 1367–1380.

[71] W. Y. Jiang, W. Xu, and F. Chen, “Dysfunction of Natural Killer Cells Promotes Immune Escape and Disease Progression in Endometriosis,” Frontiers in immunology 16 (2025): 1657605.

[72] J. L. Reis, N. N. Rosa, M. Angelo-Dias, C. Martins, L. M. Borrego, and J. Lima, “Natural Killer Cell Receptors and Endometriosis: a Systematic Review,” International Journal of Molecular Sciences 24, no. 1 (2023): 331.

[73] H. Erraji, A. El Ghanmi, N. Louanjli, et al., “Leveraging Epigenetic Aberrations in the Pathogenesis of Endometriosis: from DNA Methylation to Non-coding RNAs,” Frontiers in Genetics 16 (2025): 1597287.

[74] I. V. Bure, M. Nemtsova, and E. B. Kuznetsova, “Histone Modifications and Non-Coding RNAs: Mutual Epigenetic Regulation and Role in Pathogenesis,” International Journal of Molecular Sciences 23, no. 10 (2022): 5801.

[75] B. Ducreux, C. Patrat, J. Firmin, et al., “Systematic Review on the DNA Methylation Role in Endometriosis: Current Evidence and Perspectives,” Clin Epigenetics 17, no. 1 (2025): 32.

[76] G. Rai, A. Ashish, S. Rai, S. Mishra, S. Singh, and R. Singh, “Differential Gene Expression Profiling of Ectopic Endometrium Reveals Key Molecular Pathways in Endometriosis Pathogenesis,” Molecular Biology Reports 53, no. 1 (2026): 351.

[77] M. Skrzypczak, E. Wolinska, L. Adaszek, O. Ortmann, and O. Treeck, “Epigenetic Modulation of Estrogen Receptor Signaling in Ovarian Cancer,” International Journal of Molecular Sciences 26, no. 1 (2025): 166.

[78] R. Wu, F. F. Li, S. R. Wang, et al., “Epigenetic Programming of Estrogen Receptor in Adipocytes by High-fat Diet Regulates Obesity-induced Inflammation,” Jci Insight 10, no. 19 (2025): e173423.

[79] H. W. Kim, J. E. Park, M. Baek, et al., “Matrix Metalloproteinase-1 (MMP1) Upregulation through Promoter Hypomethylation Enhances Tamoxifen Resistance in Breast Cancer,” Cancers 14, no. 5 (2022): 1232.

[80] N. Monnin, A. J. Fattet, and I. Koscinski, “Endometriosis: Update of Pathophysiology, (Epi) Genetic and Environmental Involvement,” Biomedicines 11, no. 3 (2023): 1232.

[81] I. Psilopatis, K. Vrettou, F. N. Fleckenstein, and S. Theocharis, “The Impact of Histone Modifications in Endometriosis Highlights New Therapeutic Opportunities,” Cells-Basel 12, no. 9 (2023): 1227.

[82] S. Matsuzaki, J. L. Pouly, and M. Canis, “Persistent Activation of Signal Transducer and Activator of Transcription 3 via Interleukin-6 Trans-signaling Is Involved in Fibrosis of Endometriosis,” Human Reproduction 37, no. 7 (2022): 1489–1504.

[83] E. Soltani-Fard, M. Asadi, S. Taghvimi, et al., “Exosomal microRNAs and Long Noncoding RNAs: as Novel Biomarkers for Endometriosis,” Cell and Tissue Research 394, no. 1 (2023): 55–74.

[84] M. Abbaszadeh, M. Karimi, and S. Rajaei, “The Landscape of Non-coding RNAs in the Immunopathogenesis of Endometriosis,” Frontiers in immunology 14 (2023): 1223828.

[85] R. Z. De Oliveira, F. D. Buono, A. C. L. Cressoni, et al., “Overexpression of miR-200b-3p in Menstrual Blood-Derived Mesenchymal Stem Cells from Endometriosis Women,” Reprod Sci 29, no. 3 (2022): 734–742.

[86] Y. Rasmi, Y. A. Mohamed, S. Alipour, S. Ahmed, and S. S. Abdelmajed, “The Role of miR-143/miR-145 in the Development, Diagnosis, and Treatment of Diabetes,” J Diabetes Metab Dis 23, no. 1 (2024): 39–47.

[87] T. Szaflik, H. Romanowicz, K. Szyllo, et al., “Analysis of Long Non-Coding RNA (lncRNA) UCA1, MALAT1, TC0101441, and H19 Expression in Endometriosis,” International Journal of Molecular Sciences 23, no. 19 (2022): 11583.

[88] Y. Xu, H. W. Liu, W. Q. Xiong, et al., “A Novel Mechanism Regulating Pyroptosis-induced Fibrosis in Endometriosis via Lnc-MALAT1/miR-141-3p/NLRP3 Pathway,” Biology of Reproduction 109, no. 2 (2023): 156–171.

[89] Y. Yue, J. Qian, D. D. Gui, and B. Lu, “Circular RNAs in Endometriosis Analyzed through RNA Sequencing and Bioinformatics for Expression Profile,” Peerj 13 (2025): e19298.

[90] J. C. Nie, Y. H. Yi, X. S. Liu, and S. W. Guo, “Progressively Diminished Estrogen Signaling Concordant with Increased Fibrosis in Ectopic Endometrium,” Hum Reprod Open 2025, no. 3 (2025): hoaf028.

[91] H. C. Tang, T. C. Lin, M. H. Wu, and S. J. Tsai, “Progesterone Resistance in Endometriosis: a Pathophysiological Perspective and Potential Treatment Alternatives,” Reprod Med Biol 23, no. 1 (2024): e12588.

[92] M. H. Makoui, S. Fekri, R. H. Makoui, N. Ansari, and A. Esmaeilzadeh, “The Role of Mast Cells in the Development and Advancement of Endometriosis,” American Journal of Reproductive Immunology 93, no. 3 (2025): e70019.

[93] S. Clemenza, S. Vannuccini, A. Ruotolo, T. Capezzuoli, and F. Petraglia, “Advances in Targeting Estrogen Synthesis and Receptors in Patients with Endometriosis,” Expert Opin Inv Drug 31, no. 11 (2022): 1227–1238.

[94] K. Yu, Z. Y. Huang, X. L. Xu, J. Li, X. W. Fu, and S. L. Deng, “Estrogen Receptor Function: Impact on the Human Endometrium,” Front Endocrinol 13 (2022): 827724.

[95] Z. N. Wang, S. Guo, Y. Xie, Y. Tong, W. Qi, and Z. H. Wang, “Endometrial Expression of ERRβ and ERRγ: Prognostic Significance and Clinical Correlations in Severe Endometriosis,” Front Endocrinol 15 (2024): 1489097.

[96] P. Zhang and G. Y. Wang, “Progesterone Resistance in Endometriosis: Current Evidence and Putative Mechanisms,” International Journal of Molecular Sciences 24, no. 8 (2023): 6992.

[97] S. C. Lin, W. N. Li, S. C. Lin, et al., “Targeting YAP1 Ameliorates Progesterone Resistance in Endometriosis,” Human Reproduction 38, no. 6 (2023): 1124–1134.

[98] P. R. Koninckx, A. Ussia, L. Adamyan, V. Gomel, and D. C. Martin, “Peritoneal Fluid Progesterone and Progesterone Resistance in Superficial Endometriosis Lesions,” Human Reproduction 37, no. 2 (2022): 203–211.

[99] K. Tamura, M. Yoshie, K. Kusama, and A. Tsuru, “Mechanisms of Decidual Dysfunction and Infertility in Endometriosis: Roles of Prostaglandins and SASP,” Reprod Med Biol 24, no. 1 (2025): e12663.

[100] N. Machairiotis, S. Vasilakaki, and N. Thomakos, “Inflammatory Mediators and Pain in Endometriosis: a Systematic Review,” Biomedicines 9, no. 1 (2021): 54.

[101] Q. Zhang, S. M. Wu, Y. J. Li, et al., “Endometriosis-targeted MRI Imaging Using Bevacizumab-modified Nanoparticles Aimed at Vascular Endothelial Growth Factor,” Nanoscale Adv 5, no. 15 (2023): 3994–4001.

[102] N. L. Magner, Y. J. Jung, J. Wu, J. A. Nolta, M. A. Zern, and P. Zhou, “Insulin and IGFs Enhance Hepatocyte Differentiation From Human Embryonic Stem Cells Via The PI3K/AKT Pathway,” Stem Cells 31, no. 10 (2013): 20952103.

[103] J. Lee, S. G. Yeo, J. M. Lee, et al., “Expression of Free Radicals and Reactive Oxygen Species in Endometriosis: Current Knowledge and Its Implications,” Antioxidants-Basel 14, no. 7 (2025): 877.

[104] R. Thapa and D. Monsivais, “Mechanisms Driving Resistance to Oxidative Stress during Endometrial Stromal Cell Decidualization†,” Biology of Reproduction 114, no. 2 (2026): 511–530.

[105] L. Huang, L. Shi, M. Y. Li, X. L. Yin, and X. L. Ji, “Oxidative Stress in Endometriosis: Sources, Mechanisms and Therapeutic Potential of Antioxidants (Review),” International Journal of Molecular Medicine 55, no. 5 (2025): 72.

[106] L. Clower, T. Fleshman, W. J. Geldenhuys, and N. Santanam, “Targeting Oxidative Stress Involved in Endometriosis and Its Pain,” Biomolecules 12, no. 8 (2022): 1055.

[107] I. Dymanowska-Dyjak, K. Frankowska, M. Abramiuk, and G. Polak, “Oxidative Imbalance in Endometriosis-Related Infertility-The Therapeutic Role of Antioxidants,” International Journal of Molecular Sciences 25, no. 12 (2024): 6298.

[108] H. Ansariniya, A. Yavari, A. Javaheri, and F. Zare, “Oxidative Stress-related Effects on Various Aspects of Endometriosis,” American Journal of Reproductive Immunology 88, no. 3 (2022): e13593.

[109] L. Interdonato, R. Siracusa, R. Fusco, S. Cuzzocrea, and R. Di Paola, “Endocrine Disruptor Compounds in Environment: Focus on Women's Reproductive Health and Endometriosis,” International Journal of Molecular Sciences 24, no. 6 (2023): 5682.

[110] J. Ahn, T. Sen, D. B. Lee, et al., “Uterus-Derived Decellularized Extracellular Matrix-Mediated Endometrial Regeneration and Fertility Enhancement,” Advanced Functional Materials 33, no. 34 (2023): 2214291.

[111] M. Chen, X. M. Liu, X. X. Song, et al., “Endometrial ECM Modified Hemispherical Hydrogels Delivering MenSCs Promote the Regeneration of Thin Endometrium,” Adv Healthc Mater 15, no. 2 (2026): e01321.

[112] T. Kleimenova, V. Polyakova, N. Linkova, A. Drobintseva, D. Medvedev, and A. Krasichkov, “The Expression of Kisspeptins and Matrix Metalloproteinases in Extragenital Endometriosis,” Biomedicines 12, no. 1 (2024): 94.

[113] A. E. Butler, M. Nandakumar, T. Sathyapalan, E. Brennan, and S. L. Atkin, “Matrix Metalloproteinases, Tissue Inhibitors of Metalloproteinases, and Their Ratios in Women with Polycystic Ovary Syndrome and Healthy Controls,” International Journal of Molecular Sciences 26, no. 1 (2025): 321.

[114] S. Matsuzaki and M. Canis, “Effects of Hormonal Treatment on the Expression of Collagen Type I, Matrix Metalloproteinase-1, and Tissue Inhibitor of Metalloproteinases-1 in Endometriosis,” Eur J Obstet Gyn R B 316 (2026): 114788.

[115] N. Wei, H. B. Guan, Y. F. Zhang, et al., “Molecular Mechanisms Underlying the Inhibition of Cell Migration and Invasion in Endometriosis: Advances in Pharmacological Research (Review),” Biomed Rep 23, no. 3 (2025): 152.

[116] C. P. Hu, J. Y. Deng, M. X. Liu, et al., “Endometrial BMP2 Deficiency Impairs ITGB3-Mediated Trophoblast Invasion in Women with Repeated Implantation Failure,” Endocrinology 165, no. 3 (2024): bqae002.

[117] L. Adamyan, L. Pivazyan, L. Obosyan, et al., “Expression Profiles of E-cadherin and N-cadherin in Endometriosis and Other Gynecological Diseases towards Targeted Treatment: a Systematic Review,” Obstet Gynecol Sci 68, no. 5 (2025): 349–371.

[118] M. Szymanski, K. Bonowicz, P. Antosik, et al., “Role of Cyclins and Cytoskeletal Proteins in Endometriosis: Insights Into Pathophysiology,” Cancers 16, no. 4 (2024): 836.

[119] V. Kumarasamy, J. X. Wang, M. Roti, et al., “Discrete Vulnerability to Pharmacological CDK2 Inhibition Is Governed by Heterogeneity of the Cancer Cell Cycle,” Nature Communications 16, no. 1 (2025): 1476.

[120] Y. Ahmadi, T. Mohammed, S. Abolhasani, S. A. Hamad, and T. Faiq, “Dysregulation of the Cyclin D/E2F Activity as a Core Mechanism Driving Cancer Stem Cell Plasticity and Cell Cycle Dynamics,” Cell Cycle 25, no. 1 (2026): 1–29.

[121] A. Moïse, M. Dzeitova, L. de Landsheere, M. Nisolle, and G. Brichant, “Endometriosis and Infertility: Gynecological Examination Practical Guide,” Journal of Clinical Medicine 14, no. 6 (2025): 1904.

[122] F. G. Martire, C. Russo, A. Selntigia, et al., “Early Noninvasive Diagnosis of Endometriosis: Dysmenorrhea and Specific Ultrasound Findings Are Important Indicators in Young Women,” Fertility and Sterility 119, no. 3 (2023): 455–464.

[123] A. Roditis, M. Florin, P. Rousset, C. Touboul, S. Bendifallah, and M. Bazot, “Thomassin-Naggara I: Accuracy of Combined Physical Examination, Transvaginal Ultrasonography, and Magnetic Resonance Imaging to Diagnose Deep Endometriosis,” Fertility and Sterility 119, no. 4 (2023): 634–643.

[124] F. G. Martire, M. Giorgi, C. D'Abate, et al., “Deep Infiltrating Endometriosis in Adolescence: Early Diagnosis and Possible Prevention of Disease Progression,” Journal of Clinical Medicine 13, no. 2 (2024): 550.

[125] G. Condous, B. Gerges, I. Thomassin-Naggara, et al., “Non-Invasive Imaging Techniques for Diagnosis of Pelvic Deep Endometriosis and Endometriosis Classification Systems: an International Consensus Statement,” J Minim Invas Gyn 31, no. 7 (2024): 129–144.

[126] Z. Elias, A. Kielar, H. Arif-Tiwari, et al., “Optimizing Endometriosis Detection: a Review of Technical Approaches and Interpretative Pitfalls,” Abdom Radiol 51, no. 1 (2026): 329–345.

[127] A. Daniilidis, G. Grigoriadis, D. Dalakoura, M. N. D'Alterio, S. Angioni, and H. Roman, “Transvaginal Ultrasound in the Diagnosis and Assessment of Endometriosis-An Overview: How, Why, and When,” Diagnostics 12, no. 12 (2022): 2912.

[128] A. Bausic, C. Coroleuca, C. Coroleuca, et al., “Transvaginal Ultrasound vs Magnetic Resonance Imaging (MRI) Value in Endometriosis Diagnosis,” Diagnostics 12, no. 7 (2022): 1767.

[129] R. Galbusera, E. Bahn, M. Weigel, et al., “Postmortem Quantitative MRI Disentangles Histological Lesion Types in Multiple Sclerosis,” Brain Pathology 33, no. 6 (2023): e13136.

[130] E. Pascoal, J. M. Wessels, M. K. Aas-Eng, et al., “Strengths and Limitations of Diagnostic Tools for Endometriosis and Relevance in Diagnostic Test Accuracy Research,” Ultrasound Obst Gyn 60, no. 3 (2022): 309–327.

[131] S. M. Gratton, A. J. Choudhry, G. A. Vilos, et al., “Diagnosis of Endometriosis at Laparoscopy: a Validation Study Comparing Surgeon Visualization with Histologic Findings,” J Obstet Gynaecol Ca 44, no. 2 (2022): 135–141.

[132] Z. H. Song, S. T. Li, M. Luo, H. J. Li, H. Z. Zhong, and S. B. Wei, “Assessing the Role of Robotic Surgery versus Laparoscopic Surgery in Patients with a Diagnosis of Endometriosis: a Meta-analysis,” Medicine 102, no. 50 (2023): e33104.

[133] K. A. Stewart, D. S. Ubl, E. B. Habermann, Z. Khan, T. L. Burnett, and A. G. Cope, “Risk of Surgical Site Infection after Clean Laparoscopy for Endometriosis,” J Minim Invas Gyn 32, no. 10 (2025): 889–897.e5.

[134] M. Gracia, C. de Guirior, M. Valdés-Bango, et al., “Adenomyosis Is an Independent Risk Factor for Complications in Deep Endometriosis Laparoscopic Surgery,” Sci Rep-Uk 12, no. 1 (2022): 7086.

[135] S. L. Young, “Nonsurgical Approaches to the Diagnosis and Evaluation of Endometriosis,” Fertility and Sterility 121, no. 2 (2024): 140–144.

[136] B. S. Oskouei, Z. Asadi, and R. J. Esfahlan, “Non-invasive Blood Tests for Earlier Diagnosis and Treatment of Endometriosis,” Journal of Reproductive Immunology 169 (2025): 104521.

[137] A. Vanhie, E. Caron, E. Vermeersch, et al., “Circulating microRNAs as Non-Invasive Biomarkers in Endometriosis Diagnosis-A Systematic Review,” Biomedicines 12, no. 4 (2024): 888.

[138] Z. Yu, Y. Sun, and C. S. Guo, “Evaluating Pretreatment Serum CA-125 Levels as Prognostic Biomarkers in Endometrial Cancer: a Comprehensive Meta-analysis,” Frontiers in oncology 14 (2024): 1442814.

[139] E. Cicinelli, D. de Ziegler, and A. Vitagliano, “In Women with Endometriosis, Effective Treatment of Chronic Endometritis with Antibiotics Lowers Serum CA-125 Levels,” Fertility and Sterility 121, no. 6 (2024): 1066–1068.

[140] T. Chen, J. L. Wei, T. Leng, F. Gao, and S. Y. Hou, “The Diagnostic Value of the Combination of Hemoglobin, CA199, CA125, and HE4 in Endometriosis,” Journal of Clinical Laboratory Analysis 35, no. 9 (2021): e23947.

[141] I. M. Maier and A. C. Maier, “miRNAs and lncRNAs: Potential Non-Invasive Biomarkers for Endometriosis,” Biomedicines 9, no. 11 (2021): 1662.

[142] I. Kokot, A. Piwowar, M. Jedryka, K. Solkiewicz, and E. M. Kratz, “Diagnostic Significance of Selected Serum Inflammatory Markers in Women with Advanced Endometriosis,” International Journal of Molecular Sciences 22, no. 5 (2021): 2295.

[143] A. Visnic, D. Barisic, G. C. Juresic, M. Klaric, and T. S. Sepic, “Concentration of Total Proteins in Urine as a Non-invasive Biomarker of Endometriosis,” J Bras Reprod Assist 27, no. 4 (2023): 624–628.

[144] A. Shama, T. Soni, I. K. Jawanda, G. Upadhyay, A. Sharma, and V. Prabha, “The Latest Developments in Using Proteomic Biomarkers from Urine and Serum for Non-Invasive Disease Diagnosis and Prognosis,” Biomark Insights 18 (2023): 11772719231190218.

[145] M. F. Hua, Y. Wang, J. Yao, et al., “Analysis of Inflammatory Biomarkers IL-6, Vascular Endothelial Growth Factor and Matrix Metalloproteinases-9 Expression in Endometriosis,” Sage Open Med 13, (2025): 20503121251321625.

[146] S. Misir, C. Hepokur, B. Oksasoglu, C. Yildiz, A. Yanik, and Y. Aliyazicioglu, “Circulating Serum miR-200c and miR-34a-5p as Diagnostic Biomarkers for Endometriosis,” J Gynecol Obstet Hum 50, no. 4 (2021): 102092.

[147] Z. M. Ramadan, S. M. Mouazen, S. S. Khan, S. Khan, and N. S. Farag, “Machine Learning in the Early Detection of Endometriosis: a Literature Review on Symptom Clustering and Imaging Integration a Literature Review,” Precis Future Med 9, no. 3 (2025): 117–128.

[148] H. Dev, N. M. Falkner, and E. Lee, “Navigating Complexity: Review and Updates of Endometriosis and Adenomyosis Imaging,” Brit J Radiol 99, no. 1180 (2026): 656–668.

[149] E. P. Khashchenko, E. V. Uvarova, T. K. Fatkhudinov, et al., “Endometriosis in Adolescents: Diagnostics, Clinical and Laparoscopic Features,” Journal of Clinical Medicine 12, no. 4 (2023): 1678.

[150] B. Y. Zhang, X. L. Lv, D. Li, L. T. Zhang, Z. Y. Ru, and Y. X. Ma, “Diagnostic Accuracy of Machine Learning for Endometriosis: a Systematic Review and Meta-analysis,” Front Endocrinol 17 (2026): 1735567, (vol 16, 1735567, 2026).

[151] N. N. Zhao, T. Hao, and F. G. Zhang, “Application of Machine Learning Techniques in the Diagnosis of Endometriosis,” Bmc Womens Health 24, no. 1 (2024): 491.

[152] G. D. Gaio, F. Kemczenski, W. F. O. Amador, C. F. Farias, and J. Chagas, “Clinical Effectiveness of Progestogens Compared to Combined Oral Contraceptive Pills in the Treatment of Endometriosis: a Systematic Review and Meta-analysis,” Eur J Obstet Gyn R B 306 (2025): 219–225.

[153] H. Bennink, F. A. M. van Gennip, M. G. F. Gerrits, J. F. M. Egberts, K. Gemzell-Danielsson, and H. Kopp-Kallner, “Health Benefits of Combined Oral Contraceptives—A Narrative Review,” Eur J Contracep Repr 29, no. 2 (2024): 40–52.

[154] M. García-Sáenz, R. Ibarra-Salce, F. J. Pozos-Varela, et al., “Understanding Progestins: from Basics to Clinical Applicability,” Journal of Clinical Medicine 12, no. 10 (2023): 3388.

[155] N. Phelan, S. H. Conway, S. Llahana, and G. S. Conway, “Quantification of the Adverse Effect of Ethinylestradiol Containing Oral Contraceptive Pills When Used in Conjunction with Growth Hormone Replacement in Routine Practice,” Clinical Endocrinology 76, no. 5 (2012): 729–733.

[156] C. Z. Watling, S. Sweetland, A. Wojt, et al., “Oral Contraceptive Use and Risk of Liver Cancer: a Population-based Study, Systematic Review, and Meta-analysis,” The Lancet Oncology 26, no. 8 (2025): 1031–1042.

[157] S. Vannuccini, S. Clemenza, M. Rossi, and F. Petraglia, “Hormonal Treatments for Endometriosis: the Endocrine Background,” Rev Endocr Metab Dis 23, no. 3 (2022): 333–355.

[158] D. Zyla, D. Kuzmiuk, M. Rynkowska, M. Satora, K. Kulak, and R. Tarkowski, “Progestins—A Review of Clinical Application in Gynecology,” Annals of Medicine 58, no. 1 (2026): 2570794, (vol 57, 2570794, 2025).

[159] H. Wu, J. J. Liu, Y. ST, J. Liu, and N. Li, “Efficacy and Safety of dienogest in the Treatment of Deep Infiltrating Endometriosis: a Meta-analysis,” Eur J Obstet Gyn R B 297 (2024): 40–49.

[160] D. Pinheiro, A. M. G. Pereira, M. Antonini, I. M. A. Salgado, A. T. Dias, and R. G. C. Lopes, “Tolerability of Endometriosis Medical Treatment: a Comparison between Combined Hormonal Contraceptives and Progestins,” Bmc Womens Health 23, no. 1 (2023): 510.

[161] C. Resta, A. Moustogiannis, E. Chatzinikita, et al., “Gonadotropin-Releasing Hormone (GnRH)/GnRH Receptors and Their Role in the Treatment of Endometriosis,” Cureus J Med Science 15, no. 4 (2023): e38136.

[162] A. M. Paoletti, M. Neri, M. Pilloni, et al., “Pharmacokinetic Considerations for Gonadotropin-releasing Hormone Agonists and Antagonists to Treat Endometriosis,” Expert Opin Drug Met 21, no. 6 (2025): 649–663.

[163] M. Ciebiera, O. S. Madueke-Laveaux, S. Feduniw, et al., “GnRH Agonists and Antagonists in Therapy of Symptomatic Uterine Fibroids—Current Roles and Future Perspectives,” Expert Opin Pharmaco 24, no. 16 (2023): 1799–1809.

[164] M. M. Carneiro, “Weighing up GnRH Agonist Therapy for Endometriosis: Outcomes and the Treatment Paradigm,” Expert Opin Pharmaco 26, no. 4 (2025): 355–365.

[165] Y. Ma, W. X. Wang, and Y. Zhao, “Dienogest in Conjunction with GnRH-a for Postoperative Management of Endometriosis,” Frontiers in pharmacology 15 (2024): 1373582.

[166] G. Grigoriadis, H. Roman, F. Gkrozou, and A. Daniilidis, “The Impact of Laparoscopic Surgery on Fertility Outcomes in Patients with Minimal/Mild Endometriosis,” Journal of Clinical Medicine 13, no. 16 (2024): 4817.

[167] J. Casarin, F. Ghezzi, M. Mueller, et al., “Surgical Outcomes and Complications of Laparoscopic Hysterectomy for Endometriosis: a Multicentric Cohort Study,” J Minim Invas Gyn 30, no. 7 (2023): 587–592.

[168] T. Kolben, L. Schröder, C. Kaiser-Rix, et al., “Ablation Compared with Excision in the Surgical Management of Peritoneal Endometriosis: a Retrospective Study of Pain, Re-operation, and Pregnancy Outcomes,” Archives of Gynecology and Obstetrics 313, no. 1 (2026): 73.

[169] D. Soriano, I. Adler, J. Bouaziz, et al., “Fertility Outcome of Laparoscopic Treatment in Patients with Severe Endometriosis and Repeated in Vitro Fertilization Failures,” Fertility and Sterility 106, no. 5 (2016): 1264–1269.

[170] F. Tummers, S. I. Peltenburg, J. Metzemaekers, F. W. Jansen, and M. D. Blikkendaal, “Evaluation of the Effect of Previous Endometriosis Surgery on Clinical and Surgical Outcomes of Subsequent Endometriosis Surgery,” Archives of Gynecology and Obstetrics 308, no. 5 (2023): 1531–1541.

[171] A. J. D. Osaki and M. A. P. de Oliveira, “Laparoscopy and Robotic-assisted Surgery for Endometriosis: How Intestinal and Ovarian Involvement Impact Operative Time,” J Robot Surg 19, no. 1 (2025): 417.

[172] D. Bottomley, L. Stafford, G. Blowers, et al., “A Qualitative Analysis of the Fertility Experience and Gender Identity in Young Women Following Hysterectomy for Benign Disease,” Sex Roles 89, no. 5-6 (2023): 277–287.

[173] A. Gosset, M. Susini, F. Vidal, et al., “Quality of Life of Patients with Bilateral Oophorectomy before the Age of 45 for the Treatment of Endometriosis,” Maturitas 162 (2022): 52–57.

[174] T. T. Nguyen, C. Y. Smith, L. G. Rocca, R. WA, R. Vassallo, and M. M. D. Scrodin, “A Population-based Cohort Study on the Risk of Obstructive Lung Disease after Bilateral Oophorectomy,” Npj Prim Care Resp M no. 1 (2022): 52.

[175] U. Perrone, F. Barra, M. Anatrà, et al., “Targeting Inflammation in Endometriosis: Emerging Therapeutic Options,” Expert Opin Inv Drug 34, no. 12 (2025): 995–1009.

[176] S. Ferrero, F. Barra, G. Vatteroni, et al., “Safety of Current Strategies to Manage Moderate to Severe Pain in Patients with Endometriosis,” Expert Opinion on Drug Safety 25, no. 2 (2026): 245–258.

[177] M. E. Ramos-Nino, “Non-Hormonal Strategies in Endometriosis: Targets with Future Clinical Potential,” Journal of Clinical Medicine 14, no. 14 (2025): 5091.

[178] P. R. Koninckx, M. Craessaerts, D. Timmerman, F. Cornillie, and S. Kennedy, “Anti-TNF-α Treatment for Deep Endometriosis-associated Pain:: a Randomized Placebo-controlled Trial,” Human Reproduction 23, no. 9 (2008): 2017–2023.

[179] D. Suszczyk, W. Skiba, A. Pawlowska-Lachut, et al., “Immune Checkpoints in Endometriosis-A New Insight in the Pathogenesis,” International Journal of Molecular Sciences 25, no. 11 (2024): 6266.

[180] R. M. Marquardt, D. N. Tran, B. A. Lessey, M. S. Rahman, and J. W. Jeong, “Epigenetic Dysregulation in Endometriosis: Implications for Pathophysiology and Therapeutics,” Endocrine Reviews 44, no. 6 (2023): 1074–1095.

[181] T. H. Hsieh, C. Y. Hsu, C. W. Wu, et al., “Vorinostat Decrease M2 Macrophage Polarization through ARID1A6488delG/HDAC6/IL-10 Signaling Pathway in Endometriosis-associated Ovarian Carcinoma,” Biomedicine & Pharmacotherapy 161 (2023): 114500.

[182] M. M. Dolmans and J. Donnez, “Emerging Drug Targets for Endometriosis,” Biomolecules 12, no. 11 (2022): 1654.

[183] J. Y. Park, Y. Choi, H. D. Kim, H. H. Kuo, Y. C. Chang, and C. H. Kim, “Matrix Metalloproteinases and Their Inhibitors in the Pathogenesis of Epithelial Differentiation, Vascular Disease, Endometriosis, and Ocular Fibrotic Pterygium,” International Journal of Molecular Sciences 26, no. 12 (2025): 5553.

[184] A. C. T. Zani, F. P. Valerio, J. Meola, et al., “Impact of Bevacizumab on Experimentally Induced Endometriotic Lesions: Angiogenesis, Invasion, Apoptosis, and Cell Proliferation,” Reprod Sci 27, no. 10 (2020): 1943–1950.

[185] I. Gazzo, F. Moffa, and S. Ferrero, “Fertility Preservation in Women with Endometriosis: Oocyte Cryopreservation and Other Techniques,” Best Pract Res Cl Ob 95 (2024): 102503.

[186] D. R. Kalaitzopoulos and A. S. K. Schwartz, “Fertility Preservation in Women with Endometriosis: How, When, and for Whom?,” Journal of International Medical Research 54, no. 2 (2026): 3000605261422887.

[187] M. Semprini, E. Mastellari, V. Donno, M. Capuzzo, C. Alboni, and S. Giulini, “Fertility Preservation in Women with Endometriosis,” Hum Reprod Open 2025, no. 2 (2025): hoaf012.

[188] M. Danner, A. Rummer, S. Mangiapane, and D. von Stillfried, “How Do Interventions in Primary Care or in Emergency Departments Impact Less Urgent Patients' emergency Care Utilization? A Systematic Review,” BMC Health Services Research [Electronic Resource] 26, no. 1 (2026): 309.

[189] V. N. Bolton, C. Hayden, M. Robinson, et al., “Human Oocyte Cryopreservation: Revised Evidence for Practice,” Human Fertility 26, no. 1 (2023): 2–16.

[190] A. Hungerford, H. W. Bakos, and R. J. Aitken, “Sperm Cryopreservation: Current Status and Future Developments,” Reprod Fert Develop 35, no. 3 (2022): 265–281.

[191] A. D. Sardo, C. M. Becker, S. P. Renner, et al., “Management of Women with Endometriosis in the 21st Century,” Curr Opin Obstet Gyn 37, no. 3 (2025): 149–157.

[192] C. Noguera-Navarro, J. Candela-González, and E. Orenes-Piñero, “Nutritional Changes to Improve Female Fertility: Role of Obesity, Hormones, Dietary Patterns and Endocrine Disrupting Chemicals,” Obstetrical & Gynecological Survey 80, no. 1 (2025): 44–60.

[193] P. Chera-aree, S. Tanpong, I. Thanaboonyawat, and P. Laokirkkiat, “Clomiphene Citrate plus Letrozole versus Clomiphene Citrate Alone for Ovulation Induction in Infertile Women with Ovulatory Dysfunction: a Randomized Controlled Trial,” Bmc Womens Health 23, no. 1 (2023): 602.

[194] I. Colombi, A. Ginetti, A. Cannoni, et al., “Combine Surgery and in Vitro Fertilization (IVF) in Endometriosis-Related Infertility: When and Why,” Journal of Clinical Medicine 13, no. 23 (2024): 7349.

[195] A. M. Kotlyar and D. B. Seifer, “Women with Endometriosis Who Undergo IVF: a Contemporary Review of Therapeutic Strategies for Successful Outcomes,” Reprod Biol Endocrin 24, no. 1 (2025): 1.

[196] Y. Zeng, F. Hang, C. Y. Peng, et al., “Research Progress in Rodent Models of Endometriosis,” Journal of Reproductive Immunology 163 (2024): 104219.

[197] K. A. Burns, A. M. Pearson, J. L. Slack, et al., “Endometriosis in the Mouse: Challenges and Progress toward a ‘Best Fit’ Murine Model,” Front Physiol 12 (2022): 806574.

[198] M. A. Tejada, C. Antunez, P. Nunez-Badinez, et al., “Rodent Animal Models of Endometriosis-Associated Pain: Unmet Needs and Resources Available for Improving Translational Research in Endometriosis,” International Journal of Molecular Sciences 24, no. 3 (2023): 2422.

[199] J. K. Chauhan, P. K. Dubey, S. Rai, and A. Tripathi, “Induction and Characterization of a Rat Model of Endometriosis,” Sci Rep-Uk 14, no. 1 (2024): 18827.

[200] Y. L. Zhao, Y. Wang, P. L. Gu, L. Tuo, L. L. Wang, and S. W. Jiang, “Transgenic Mice Applications in the Study of Endometriosis Pathogenesis,” Frontiers in Cell and Developmental Biology 12 (2024): 1376414.

[201] J. C. Rosa-e-Silva, S. B. Garcia, A. Rosa-e-Silva, et al., “Increased Cell Proliferation in Experimentally Induced Endometriosis in Rabbits,” Fertility and Sterility 93, no. 5 (2010): 1637–1642.

[202] T. Q. Li, R. W. S. Chan, C. L. Lee, et al., “WNT5A Interacts with FZD5 and LRP5 to Regulate Proliferation and Self-Renewal of Endometrial Mesenchymal Stem-Like Cells,” Frontiers in Cell and Developmental Biology 10 (2022): 837827.

[203] S. Liu, X. Y. Li, Z. Y. Gu, et al., “Single-cell and Spatial Transcriptomic Profiling Revealed Niche Interactions Sustaining Growth of Endometriotic Lesions,” Cell Genom 5, no. 1 (2025): 100737.

[204] B. H. M. Liu, Y. Z. Lin, X. Long, et al., “Utilizing AI for the Identification and Validation of Novel Therapeutic Targets and Repurposed Drugs for Endometriosis,” Advancement of Science 12, no. 5 (2025): e2406565.

[205] S. J. He, H. H. Li, L. Wan, and X. Y. Qin, “Global Landscape of Clinical Trials for Endometriosis: Dynamic Trends and Future Directions,” Int J Surg 111, no. 10 (2025): 7355–7358.

[206] C. E. Miller, J. H. Kim, R. Kroll, et al., “Efficacy, Tolerability, and Bone Density Outcomes of elagolix with Add-back Therapy for Endometriosis-associated Pain: Twelve Months of an Ongoing Randomized Phase 3 Trial,” American Journal of Obstetrics and Gynecology 231, no. 6 (2024): 630.e1–630.e13.

[207] S. Parke, K. Gude, K. Roth, and F. Messina, “Efficacy and Safety of eliapixant in Endometriosis-associated Pelvic Pain: the Randomized, Placebo-controlled Phase 2b SCHUMANN Study,” Bmc Womens Health 24, no. 1 (2024): 353.

[208] F. Arbelaez, H. K. Joeng, A. Hussain, et al., “Randomized, Controlled Proof-of-concept Trial of gefapixant for Endometriosis-related Pain,” Fertility and Sterility 123, no. 2 (2025): 280–288.

Rights & permissions

2026 The Author(s). MedComm published by Sichuan International Medical Exchange & Promotion Association (SCIMEA) and John Wiley & Sons Australia, Ltd.